RegulationPRIME (European Union), Conditional marketing approval (China), Fast Track (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China)

Structure/Sequence

Sequence Code 25650570L

Source: *****

Sequence Code 25650568H

Source: *****

Clinical Trials associated with Emapalumab-LZSG

NCT06694701

/ RecruitingPhase 2IIT

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.

Start Date22 Mar 2025

Sponsor / Collaborator

Hellenic Institute for the Study of Sepsis

NCT06550141

/ RecruitingPhase 2IIT

A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
* Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
* Axicabtagene Ciloleucel
* Emapalumab

Start Date18 Sep 2024

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT06285825

/ RecruitingPhase 2IIT

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.

Start Date05 Jul 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Emapalumab-LZSG

100 Translational Medicine associated with Emapalumab-LZSG

100 Patents (Medical) associated with Emapalumab-LZSG

Literatures (Medical) associated with Emapalumab-LZSG

01 Apr 2025·Rheumatology

Acute respiratory distress syndrome after emapalumab treatment in a child with severe Still’s disease and lung involvement: a case report

Article

Author: Anselmi, Federica ; Despert, Véronique ; Rossi-Semerano, Linda ; Dusser, Perrine ; Terzic, Arnaud ; Koné-Paut, Isabelle

01 Apr 2025·Clinical Rheumatology

Salvage treatment of AOSD-associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy

Article

Author: Yin, Yufeng ; Huang, Xiaoping ; Wang, Yan ; Xu, Chuancai ; Xiang, TianDan ; Li, Wenting ; Huang, Yan ; Xu, Ying ; Sun, Wei ; Zhou, Jin

OBJECTIVESAdult-onset Still's disease (AOSD)-associated macrophage activation syndrome (MAS) is a highly inflammatory condition. Currently, the main treatment method for AOSD-associated MAS is high-dose glucocorticoid shock therapy, but the effect is not satisfactory, and new therapeutic methods or drugs are urgently needed. The aim of this study was to evaluate the efficacy and safety of salvage baricitinib therapy for AOSD-associated MAS following conventional immunosuppressive therapy.METHODData from nine patients with MAS treated in the Department of Infection and the Department of Rheumatology, First Affiliated Hospital of Soochow University, from January 2020 to December 2022, were retrospective analysed. Salvage therapy with baricitinib was administered, with an initial dose of 8 mg/day. The patients' clinical symptoms and MAS indices (blood counts and triglyceride, fibrinogen, lactate dehydrogenase, sCD25, and Fer levels) were observed. After a complete response was achieved, the baricitinib dose was gradually reduced to 2-4 mg/day and maintained.RESULTSThe MAS blood test results of all nine patients improved to varying degrees within 1 week post-treatment. The MAS indices gradually returned to normal approximately 8 weeks after discharge; at the 12-month outpatient follow-up, seven patients did not develop MAS again, but two patients (patients 5 and 9) had MAS recurrence. The follow-up period ended with salvage treatment with emapalumab.CONCLUSIONSBaricitinib can effectively inhibit the inflammatory response and improve outcomes in the treatment of MAS secondary to rheumatic immunity-related diseases; moreover, this drug treatment is safe. Our study provides a new strategy for MAS salvage therapy. Key Points • Bariticinib may be a palliative treatment option for recurrent/refractory MAS.

21 Mar 2025·Leukemia & Lymphoma

Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome

Review

Author: Cerhan, James R. ; Witzig, Thomas E. ; Zoref-Lorenz, Adi ; Jordan, Michael B.

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by uncontrolled immune activation. While traditionally associated with genetic mutations affecting cytotoxic function, recent advances have highlighted the prevalence and significance of HLH in adults, particularly in hematologic malignancies. This review focuses on malignancy-associated HLH (M-HLH), a complex and challenging condition with a poor prognosis. The review explores four main subtypes of M-HLH: (1) HLH as the initial presentation of malignancy, (2) Chemotherapy Associated HLH, (3) Cytokine Release Syndrome (CRS) Associated HLH-like Syndrome, and (4) immune effector cell-associated HLH-like syndrome. Diagnosis is complicated by overlap with cancer symptoms and limitations of existing criteria. The Optimized HLH Inflammatory (OHI) index shows promise in early identification of hyperinflammation in new-onset hematologic malignancies. Treatment approaches must balance controlling hyperinflammation with addressing the underlying malignancy. Emerging therapies, including targeted agents like anakinra, ruxolitinib, and emapalumab, offer new management possibilities. This review examines the current understanding of M-HLH pathophysiology, diagnostic approaches, and treatment strategies for each subtype. It underscores the critical need for further research to unravel underlying mechanisms and establish evidence-based treatment protocols. Given the complexity of M-HLH, international collaborative efforts are essential to advance knowledge and improve patient outcomes.

News (Medical) associated with Emapalumab-LZSG

19 Mar 2025

·www.prnewswire.com

Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress

STOCKHOLM, March 19, 2025 /PRNewswire/ -- Sobi ® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS) which is to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress by Prof. Giamarellos-Bourboulis, from the Hellenic Institute for the Study of Sepsis. The study underscores Sobi's commitment to advancing medicine through targeted therapies for severe and complex conditions such as sepsis, a leading cause of mortality globally. Key Highlights IDS is a new endotype representing approximately 20 percent of sepsis patients and is characterised by detection of IFNγ (above lower limit of detection) and elevated levels of the chemokine CXCL9. The EMBRACE phase 2a study will investigate the potential of Gamifant® (emapalumab) in treating a subgroup of sepsis patients driven by the IDS endotype and absence of sepsis-induced immunoparalysis. IDS patients with a low human leukocyte antigen DR (HLA-DR) expression on monocytes characteristic of immunoparalysis will not be included into the EMBRACE study. The potential inclusion of this IDS sub-population into further studies will be evaluated based on the results of EMBRACE. The EMBRACE phase 2a trial (NCT06694701) was approved in March 2025. The first trial sites have been initiated, and patient screening to identify eligible patients with IDS has started. The trial design is to be presented at ISICEM by Prof. Evangelos Giamarellos-Bourboulis, MD, PhD, FISAC, principal investigator and sponsor of the EMBRACE study, from the Hellenic Institute for the Study of Sepsis (HISS): "The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS endotype, a patient group currently having limited therapeutic choices." "We are looking forward to this research collaboration on the use of Gamifant® (emapalumab) in the new endotype of interferon gamma-driven sepsis," said Lydia Abad-Franch, MD, Head of Research & Development and Medical Affairs and Chief Medical Officer at Sobi. "We are committed to advancing science and study Gamifant® (emapalumab) in indications with a high unmet need and where excessive interferon gamma production plays a key role in driving hyperinflammation." Presentation details Emapalumab treatment for anticipated clinical benefit in sepsis driven by the interferon-gamma endotype (the EMBRACE trial): O Konstantinidou, E Olntasi, H Florou, A Reininger, E Giamarellos-Bourboulis, F EMBRACE STUDY GROUP. ISICEM 2025; Abstract number A173; Poster number P249. About sepsis and IFNγ-driven sepsis (IDS) Sepsis is a serious condition in response to an infection that can lead to organ failure and is a leading global cause of mortality. A recent large study, published in eBioMedicine in 20241, describes different sepsis endotypes, suggesting varying endotypes require differentiated treatment strategies. Approximately 20% of the patients studied are of the newly described IFNγ-driven sepsis (IDS) endotype. IDS is marked by elevated levels of CXCL9 and detection of IFNγ and poor clinical outcomes, with a 28-day mortality rate ranging from 40 to 43%. About the EMBRACE study The EMBRACE study (NCT06694701) is a Phase 2a, double-blind, randomized controlled trial planned to be conducted at 24 sites in Greece. The trial investigates whether Gamifant® (emapalumab), an anti-IFNγ antibody, can improve clinical outcomes in patients with the interferon-gamma-driven sepsis (IDS) endotype and absence of sepsis-induced immunoparalysis. IDS is characterized by elevated levels of CXCL9 and detectable IFNγ and is associated with poor patient outcomes. By targeting this inflammation pathway, the EMBRACE trial aims to reduce mortality, improve organ function, and accelerate recovery. The trial design includes three arms, and plans to enrol 75 patients, two groups receiving Gamifant® (emapalumab), (low and high doses) alongside standard-of-care treatment, and one group receiving placebo alongside standard-of-care treatment. The primary endpoint is a ≥1.4-point decrease in the Sequential Organ Failure Assessment (SOFA) score from baseline to the end of treatment (28 days). Secondary endpoints include 28-day mortality, safety, pharmacokinetics, and changes in key inflammatory biomarkers such as CRP, IL-6, ferritin, IFNγ, and CXCL9. About Gamifant® (emapalumab) Gamifant® (emapalumab) is an anti-interferon gamma (IFNγ) monoclonal antibody that binds to and neutralises IFNγ. In the USA, Gamifant® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Primary HLH is a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Gamifant® (emapalumab) is indicated for administration through intravenous infusion over one hour twice per week until haematopoietic stem cell transplantation (HSCT) About Sobi® Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care. Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. 1: Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality Giamarellos-Bourboulis, Evangelos J. et al. eBioMedicine, Volume 109, 105414 Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Drug ApprovalImmunotherapy

28 Feb 2025

·www.pharmaceutical-technology.com

FDA accepts Sobi’s Gamifant application for HLH/MAS treatment

Sobi’s Gamifant was previously approved by the US regulator in 2018. © Swedish Orphan Biovitrum AB. The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant (emapalumab-Izsg) for haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) associated with Still’s disease. The application, which seeks approval for use in both adult and paediatric individuals who show an insufficient response or are not tolerant to glucocorticoids, or with recurrent MAS, has received priority review status. A Prescription Drug User Fee Act date was set by the agency for 27 June 2025. The sBLA is supported by pooled data outcomes from the EMERALD and NI-0501-06 studies, which enrolled a total of 39 subjects. 53% of subjects achieved a complete response by week 8 and 85% at any time during the studies. Sobi chief medical officer and research and development head Lydia Abad-Franch stated: “HLH/MAS in Still’s disease is a serious and potentially fatal complication where patients can experience intense hyperinflammation and even multiple organ failure. “Gamifant (emapalumab-Izsg) selectively neutralises interferon-gamma (IFN-γ), a key driver of hyperinflammation, and if approved, may also help reduce the need for high-dose glucocorticoids in these patients.” The therapy was previously approved by the US regulator in 2018 to treat primary HLH in adult and paediatric patients, including newborns, with refractory, recurrent or progressive conditions, or those who are not tolerant to conventional HLH therapies. A critical complication of rheumatic conditions, HLH/MAS is most commonly observed in Still’s disease, including systemic juvenile idiopathic arthritis and adult-onset Still’s disease. It is marked by severe inflammation, presenting with symptoms such as persistent high fever, elevated levels of ferritin, cytopenias, hepatosplenomegaly and coagulopathies. The company received marketing authorisation from the European Commission in June 2024 for Altuvoct (efanesoctocog alfa), a treatment designed for haemophilia A patients to manage bleeds and provide perioperative prophylaxis.

Drug ApprovalClinical ResultPriority ReviewNDA

27 Feb 2025

·www.prnewswire.com

US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. The application was granted Priority Review with a PDUFA date of June 27, 2025. HLH/MAS, a form of HLH, is a severe complication of rheumatic diseases, occurring most frequently in Still's disease including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD). HLH/MAS is a rare systemic disorder of hyperinflammation with common clinical manifestations such as high persistent fever, elevated ferritin, cytopenias, coagulopathies, and hepatosplenomegaly. "HLH/MAS in Still's disease is a serious and potentially fatal complication where patients can experience intense hyperinflammation and even multiple organ failure," said Lydia Abad-Franch, MD, MBA, Head of R&D and Chief Medical Officer at Sobi. "There is no approved therapy for HLH/MAS today. Gamifant® (emapalumab-Izsg) selectively neutralizes interferon gamma (IFN-γ), a key driver of hyperinflammation, and if approved, may also help reduce the need for high-dose glucocorticoids in these patients." The application is based on results from pooled data from two studies which enrolled a total of 39 patients, the EMERALD (NCT05001737) and the NI-0501-06 (NCT03311854) studies. Fifty-three percent of patients had a complete response at Week 8 and 85% had a complete response at any time during the studies. Weekly mean glucocorticoid doses were reduced by 70.1% after 2 weeks of treatment. Gamifant® (emapalumab-Izsg) a monoclonal antibody that binds and neutralises interferon gamma (IFN-y), was approved by the FDA in 2018 for the treatment of adult and paediatric (newborn and older) patients with primary HLH with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. About macrophage activation syndrome (MAS) Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD). MAS is characterised by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities and hyperferritinemia, possibly progressing to multiple organ failure and death. MAS is classified as a form of hemophagocytic lymphohistiocytosis (HLH). About Gamifant® (emapalumab-lzsg) Gamifant® (emapalumab-lzsg) is an anti-interferon gamma (IFN-γ) monoclonal antibody that binds to and neutralises IFN-γ. In the USA, Gamifant® (emapalumab-lzsg) is the first and only treatment approved by the FDA for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Primary HLH is a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Gamifant® (emapalumab-lzsg) is indicated for administration through intravenous infusion over one hour twice per week until hematopoietic stem cell transplantation (HSCT). About Sobi® Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPriority ReviewClinical Result

100 Deals associated with Emapalumab-LZSG

External Link

KEGG	Wiki	ATC	Drug Bank
-	Emapalumab-LZSG	L04AA39	DB14724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lymphohistiocytosis, Hemophagocytic	United States	NovImmune SA	20 Nov 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphohistiocytosis, Hemophagocytic	NDA/BLA	United States	Swedish Orphan Biovitrum AB	27 Feb 2025
Macrophage Activation Syndrome	NDA/BLA	United States	Swedish Orphan Biovitrum AB	27 Feb 2025
Still's Disease, Adult-Onset	Phase 3	United Kingdom	Swedish Orphan Biovitrum AB	15 Dec 2021
Immune System Diseases	Preclinical	European Union	Swedish Orphan Biovitrum AB	23 Jul 2020
COVID-19	Preclinical	United States	Swedish Orphan Biovitrum AB	02 Apr 2020
COVID-19	Preclinical	Italy	Swedish Orphan Biovitrum AB	02 Apr 2020
Inflammation	Preclinical	United States	Swedish Orphan Biovitrum AB	02 Apr 2020
Inflammation	Preclinical	Italy	Swedish Orphan Biovitrum AB	02 Apr 2020
Respiratory Distress Syndrome	Preclinical	Italy	Swedish Orphan Biovitrum AB	02 Apr 2020
Respiratory Distress Syndrome	Preclinical	United States	Swedish Orphan Biovitrum AB	02 Apr 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2024	Not Applicable	-	-	Emapalumab	yauhyiaomp(fxdsafvmpj) = xwqpwbwoil vxrqisbpub (cggzlvtudz )	-	01 Feb 2024
NCT04765553 (CTgov)	Phase 1	Rare Diseases	8	NI-0501 (Emapalumab)	xlskblsjcf(dsehtvmksp) = hqkkxauqqg lueoyejuhd (igfuhlpqez, iaiockgzyk - iefsjxgziv) View more	-	24 Nov 2023
NCT04765553 (CTgov)	Phase 1	Rare Diseases	8	Saline (Placebo)	fcixacarwn(nxjwkmyrfu) = hbszpzqkws ldprqfvrif (vqqakwczob, ialqztkuvd - uvalhzqdfh) View more	-	24 Nov 2023
NCT03985423 (CTgov)	Phase 2/3	Lymphohistiocytosis, Hemophagocytic	7	Emapalumab-Lzsg	oytajuwqba(uzldxhcdhe) = mwswvhvxzq pphauzrnqg (rdqudhphbb, rtkibunxvn - wqbcchljia) View more	-	06 Oct 2023
P353 (EBMT2023)	Phase 2	IFNÎ³ \| CXCL9	1	Emapalumab 3 mg/kg	(jqrwrappmg) = nxjcjbsovk jsizbpxxsw (stzckzsnfx ) View more	Positive	23 Apr 2023
NCT04731298 (P449, EBMT2022)	Phase 2	CXCL9	10	Emapalumab	bhgeolfrah(nkkcsgubzk) = nwveadjyoe nvahddxjvc (cgctiayofp ) View more	Positive	19 Mar 2022
NCT02069899 \| NCT01818492 (Tandem Meetings ASTCT and CIBMTR2021)	Phase 2/3	Lymphohistiocytosis, Hemophagocytic Second line	45	Emapalumab 1 mg/kg	jxgiiskduc(upgvvuekjq) = bjiucqkwcg frusatxhoj (lrnvhwjqbw, 68.3 - 97.6) View more	Positive	01 Mar 2021
	Phase 2/3	Lymphohistiocytosis, Hemophagocytic Second line	45	Background dexamethasone 5-10 mg/m2	jxgiiskduc(upgvvuekjq) = oignhxxstx frusatxhoj (lrnvhwjqbw, 62.1 - 92.1) View more	Positive	01 Mar 2021
NCT02069899 \| NCT01818492 (NI-0501-04 \| NI-0501-05, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 2/3	Lymphohistiocytosis, Hemophagocytic First line	34	Emapalumab (previously treated)	zvrwkrcaho(bfbgnykgfm) = istuebcogy ohwpidmmlh (avvqqgzone ) View more	Positive	07 May 2020
	Phase 2/3	Lymphohistiocytosis, Hemophagocytic First line	34	Emapalumab (previously untreated)	zvrwkrcaho(bfbgnykgfm) = bsffrotgvx ohwpidmmlh (avvqqgzone ) View more	Positive	07 May 2020
ACR2016	Not Applicable	Macrophage Activation Syndrome IFNγ \| CXCL9 \| CXCL10	-	NI-0501	cpiuvpzubt(bxnidfbimy) = kykslykbgv xvthnfbmak (erydlkqdxe )	Positive	15 Nov 2016
NI-0501 (ACR2015)	Not Applicable	Lymphohistiocytosis, Hemophagocytic \| Autoinflammation With Infantile Enterocolitis IL-18 \| IFNγ \| CXCL9 ... View more	1	NI-0501	dokjgfwqjx(msmmkdrrar) = jvchyshrrj rkiwjsodiq (ptewkpsypd )	Positive	10 Nov 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis